Jagath Reddy Junutula
President, Chief Executive Officer & Co- Founder Aarvik Therapeutics
Jagath Reddy is the Co‑founder, President, and CEO of Aarvik Therapeutics, where he leads the company’s vision to advance innovative oncology treatments through next‑generation therapeutic platforms. With more than a decade of leadership across emerging biotech, he has guided R&D strategy, clinical development, and company building as Senior Vice President of R&D and Chief Development Officer at AntlerA Therapeutics and as Co‑founder of multiple startups. Jagath also serves on the Boards of Aarvik Therapeutics and EPOK Therapeutics and previously contributed to NJ Bio’s Scientific Advisory Board, bringing deep expertise in drug discovery, translational development, and biotech innovation.
Seminars
- Incorporating flexible, hydrophilic chains directly on linker cores to create a dynamic solubility shield around the hydrophobic payload, prevent both intermolecular aggregation and non-specific hydrophobic interactions
- Integrating modules into the linker design to leverage innate hydrophilicity and biocompatibility, significantly improving the aqueous solubility and biophysical profile of the entire ADC
- Designing linkers with charged groups to fine-tune the overall hydrophilic-lipophilic balance of the conjugate optimizing its serum stability
